Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IMPDH2 | P12268 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15597759 | 1.00 | IMPDH2 (0.59) | IMPDH2KDM4EALDH1A1NPC1TP53 | |
| SCHEMBL15568041 | 1.00 | IMPDH2 (0.59) | IMPDH2KDM4EALDH1A1NPC1TP53 | |
| SCHEMBL16939872 | 0.93 | IMPDH2 (0.62) | IMPDH2KDM4EALDH1A1NPC1TP53 | |
| SCHEMBL15597621 | 0.86 | IMPDH2 (0.78) | IMPDH2KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL15597670 | 0.86 | IMPDH2 (0.78) | IMPDH2KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL15597671 | 0.86 | IMPDH2 (0.78) | IMPDH2KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL13182379 | 0.83 | KDM4E (0.69) | KDM4EALDH1A1HPGDHSD17B10MAPT | |
| SCHEMBL15598247 | 0.83 | KDM4E (0.69) | KDM4EALDH1A1HPGDHSD17B10MAPT | |
| SCHEMBL15598248 | 0.83 | KDM4E (0.69) | KDM4EALDH1A1HPGDHSD17B10MAPT | |
| SCHEMBL16942520 | 0.82 | ALDH1A1 (0.69) | KDM4EALDH1A1NPC1TP53HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9447134-B2 | Compounds and methods for treating mammalian gastrointestinal microbial infections | BRANDEIS UNIVERSITY (US) | 2016-09-20 | — | — | US | disclosed |
| US-20150210727-A1 | COMPOUNDS AND METHODS FOR TREATING MAMMALIAN GASTROINTESTINAL MICROBIAL INFECTIONS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2015-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150210727-A1 | COMPOUNDS AND METHODS FOR TREATING MAMMALIAN GASTROINTESTINAL MICROBIAL INFECTIONS | IMPDH1, IMPDH2, IMPA1 | IMPDH2 2/4885KDM4E 2734/4885ALDH1A1 57/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.